Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination
Explore this paper's citation graph
Summary
The data indicates that the natural infection induces a more robust humoral immune response than the first vaccine dose in unexposed subjects, and the difference was significant only when the neutralization was measured but not by assessing the total anti-S antibodies or the IgG titers.
- Type
- preprint
- Published
- 2021-06-03
- Cited by
- 21
- References
- 43
- Access
- Open access
- OpenAlex
- https://openalex.org/W3164617264
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:235311092
Keywords
Antibody, Neutralizing antibody, Titer, Neutralization, Isotype
References
- In patients with rheumatoid arthritis IgG binding to denatured collagen type II is in part mediated by IgG-fibronectin complexes.
- Non-specific binding in solid phase immunoassays for autoantibodies correlates with inflammation markers.
- Atomic force microscopy analysis of IgG films at hydrophobic surfaces: a promising method to probe IgG orientations and optimize ELISA tests performance.
- Translating innate immunity into immunological memory: implications for vaccine development.
- Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- Effective control of early Zika virus replication by Dengue immunity is associated to the length of time between the 2 infections but not mediated by antibodies
- Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma
- Validation and performance of a quantitative IgG assay for the screening of SARS-CoV-2 antibodies
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
- Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
- SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
- Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
- The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera
- Presence and short‐term persistence of SARS‐CoV‐2 neutralizing antibodies in COVID‐19 convalescent plasma donors
- Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
- Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Cited by
- Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2
- Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population
- SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
- Immune responses to inactivated and vector-based vaccines in individuals previously infected with SARS-CoV-2
- Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals
- Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort
- Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic
- Immunogenesis in patients with medium and severe coronavirus infection – dynamics in different age groups
- Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
- Serological Responses up to 9 Months following COVID-19 mRNA Vaccination in Residents and Health-Care Workers of Long-Term Care Facilities: A Multicenter Prospective Cohort Study in Northern Italy
- Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic
- Antibody titers of individuals vaccinated for COVID-19: A systematic review
- Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients
- The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer–BioNTech Vaccine
- Accuracy of Anti-SARS-CoV-2 Antibody in Comparison with Surrogate Viral Neutralization Test in Persons Living with HIV, Systemic Lupus Erythematosus, and Chronic Kidney Disease
- Vaccine‐induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?
- Anti-SARS-CoV-2 IgM Antibody Levels Measured by an In-House ELISA in a Convalescent Latin Population Persist over Time and Exhibit Neutralizing Capacity to Several Variants of Concern
- Distinct Neutralising and Complement-Fixing Antibody Responses Can Be Induced to the Same Antigen in Haemodialysis Patients After Immunisation with Different Vaccine Platforms
- Long-term dynamics of natural, vaccine-induced, and hybrid immunity to SARS-CoV-2 in a university hospital in Colombia: A cohort study
- Vaccine‐Induced Humoral Response of BNT162b2 and MRNA-1273 Against BA.1, BA.5, and XBB.1.5. (Sub)Variants 6 Months after a Homologous Booster: Is Immunogenicity Equivalent?
Related papers
- Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
- Binding and Neutralization Activity of Human IgG1 and IgG3 from Serum of HIV-Infected Individuals
- Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
- Heterogeneity in the properties of 7 S and 19S rabbit-neutralizing antibodies to herpes simplex virus.
- Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
- Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma
- Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
- Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.
- Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum